GLP-1s reduce heart failure death, hospitalization: 3 things to know
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.
Researchers from Somerville, Mass.-based Mass General Brigham analyzed U.S. insurance claim data to emulate two previous semaglutide and tirzepatide trials at a larger scale, an Aug. 31 news release from the health system said.
The analysis compared the one-year risk of heart failure hospitalization or death among new users of semaglutide or tirzepatide to the one-year risk of heart failure hospitalization or death among patients only taking the diabetes drug sitagliptin.
Here are three notes from the study:
- Semaglutide is a glucagon-like peptide-1 receptor agonist sold under the brand names Ozempic and Wegovy.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide sold under the brand names Mounjaro and Zepbound.
- Both semaglutide and tirzepatide were associated with a more than 40% reduction in heart failure hospitalization or all-cause mortality when compared with sitagliptin.
Semaglutide and tirzepatide had similar rates of effectiveness and safety profiles.
- “By using nationwide data and an innovative methodological approach, our team was able to expand the findings of previous trials to larger populations more representative of [heart failure with preserved ejection fraction] patients treated in clinical practice,” Nils Krüger, MD, corresponding study author, said in the release. “Our findings show that in the future, GLP-1 targeting medications could provide a much-needed treatment option for patients with heart failure.”
Read the full study here.
The post GLP-1s reduce heart failure death, hospitalization: 3 things to know appeared first on Becker’s Hospital Review | Healthcare News & Analysis.